Clinical trial · Observational
Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Terminated per PI's request
Summary
Brief summary (as posted)
This trial studies how well cardiac biomarkers work in the early detection of cardiotoxicity in patients receiving sunitinib malate or sorafenib chemotherapy. Some chemotherapies are known to cause damage to heart muscle cells, resulting in heart failure. Often, the damage is not detected until heart failure has already occurred. Testing for cardiac biomarkers, such as troponin I and/or T and B-type natriuretic peptide (BNP), may be useful in detecting heart damage earlier than other tests currently performed (such as echocardiogram and electrocardiogram).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Neoplasm | Malignant Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biospecimen Collection | Procedure | — | UNRESOLVED |
| Questionnaire Administration | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ancillary-correlative (biospecimen collection)
- description
- Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2 weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.
- interventionNames
- Procedure: Biospecimen Collection
- Other: Questionnaire Administration
Primary outcomes (2)
- measure
- Sensitivity of each biomarker for detecting cardiotoxicity
- timeFrame
- Up to 6 months
- description
- Will estimate with exact 95% confidence intervals.
- measure
- Specificity of each biomarker for detecting cardiotoxicity
- timeFrame
- Up to 6 months
- description
- Will estimate with exact 95% confidence intervals.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patient age 18-85 years * Starting a new course of chemotherapy at MD Anderson Cancer Center that includes sunitinib or sorafenib * Has a life expectancy of greater than 6 months Exclusion Criteria: * Unstable angina within the last 3 months * Myocardial infarction within the last 3 months * Left ventricular ejection fraction (LVEF) less than 40% * Decompensated heart failure (HF) in the last 3 months
References
Publications (0)
Data not yet available